Shares of Dr. Reddy's Laboratories experienced a dip on Thursday following two significant announcements that are set to influence the company's near-term market performance. The pharmaceutical firm disclosed that the US Food and Drug Administration (US FDA) issued a Form 483 with two observations after a recent inspection of its FTO-11 manufacturing unit in Andhra Pradesh. Concurrently, the company announced the date for its second-quarter and half-year financial results for the period ending September 30, 2026.
US FDA Flags Observations at Andhra Pradesh Facility
The US FDA conducted a Pre-Approval Inspection (PAI) at Dr. Reddy's FTO-11 manufacturing facility, located in Pydibhimavaram, Andhra Pradesh. The inspection took place from October 5 to October 7, 2026. Following the assessment, the regulatory body issued a Form 483, detailing two observations. Dr. Reddy's Laboratories has stated its commitment to addressing these observations within the stipulated timeframe, a standard procedure for such regulatory findings.
Q2 and Half-Year Results Scheduled for October 23
In addition to the regulatory update, Dr. Reddy's Laboratories confirmed that its Board Meeting on Friday, October 23, 2026, will include the announcement of the company's financial results for the quarter and six months concluded on September 30, 2026. An earnings call is scheduled to follow the release, where management will discuss the company's financial performance and outlook with investors and analysts.
Stock Performance and Previous Quarter's Context
On Thursday, Dr. Reddy's Laboratories shares closed 1.86% lower at Rs 1180, with the company's market capitalization standing at Rs 98,487 crore. The upcoming financial results will be closely watched, especially in light of the previous quarter's performance. In the first quarter of the current fiscal year (April-June), the Hyderabad-based drug maker reported a substantial 69% decline in consolidated net profit, reaching Rs 443 crore, compared to Rs 1,418 crore in the corresponding period of the prior fiscal year. Revenue from operations also saw a 5.6% decrease to Rs 8,070.5 crore.
This downturn in Q1 was primarily attributed to inventory and related costs stemming from disruptions in semaglutide supplies, alongside pricing pressures and heightened competition within its crucial US market. The company had made a provision of Rs 240 crore to cover these semaglutide-related costs during the first quarter.